title: Paraplegia and quadriplegia after intrathecal chemotherapy.
abstract: Transient or permanent paraplegia after the use of intrathecal (IT) methotrexate (MTX) or cytosine arabinoside (Ara-C) for treatment or prophylaxis of patients with meningeal leukemia is an unusual complication, with an incidence of less than 3% among such patients. Only 15 cases involving IT MTX have been documented and even fewer with IT Ara-C. Three patients were studied who developed permanent or ascending myelopathy from treatment of their leukemia or rhabdomyosarcoma with IT chemotherapy. The patients' ages ranged from 7 to 62 years. Two of the three patients had electromyographic examinations. These revealed a primary motor neuron degeneration or a polyradiculopathy, superimposed on a mild axonal peripheral neuropathy associated with vincristine therapy. This is consistent with other electromyographic studies. Two of the patients showed an elevation of the cerebral spinal fluid (CSF) protein before development of paraplegia; one also showed a rise in myelin basic protein associated with his myelopathy. Neuropathologic findings suggest demyelination as the primary process leading to myelopathy. Increasing evidence has shown that total CSF protein, or more specifically, the myelin basic protein, may be elevated before development of paraplegia. Routine serial testing of the CSF for total protein could be used as a screening test during therapy.
authors.affiliation: Department of PM&R, University of Michigan Medical Center, Ann Arbor 48109-0042.
authors.forename: R A
authors.initials: RA
authors.lastname: Werner
mesh_terms: D000328:Adult; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007278:Injections, Spinal / Q000009:adverse effects*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D010264:Paraplegia / Q000209:etiology*; D011782:Quadriplegia / Q000209:etiology*; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy
chemical_list: D003561:Cytarabine; D008727:Methotrexate